Weekly Digest - April 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - April 2025
03 Apr 2025: Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D centre in Basel
- Boehringer Ingelheim has invested $31 million to establish a new antibody-drug conjugate (ADC) R&D facility in Basel through its subsidiary, NBE Therapeutics, to advance cancer treatment
- The new facility strengthens Boehringer Ingelheim’s oncology research strategy and enhances its presence in Switzerland’s biotech ecosystem
- NBE Therapeutics focuses on developing next-generation ADCs that target cancer cells while minimizing damage to healthy tissue, aiming to improve patient quality of life
- This expansion complements Boehringer Ingelheim’s global oncology network, fostering collaborations with other biotech companies and accelerating innovative cancer therapies
